This website is a resource intended for New Zealand healthcare professionals who are interested in information on Foundation Medicine®. If you are a New Zealand consumer, click here. These sites are not intended to provide medical advice and/or treatment guidance.  

This site is produced by Roche as a partner of Roche Foundation Medicine.


Thank you for visiting our site.

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control the content of any linked websites and if you click OK, you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet. Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Click OK to continue.

Discover how comprehensive genomic profiling from Foundation Medicine may help open up treatment possibilities for you1–3

Your cancer’s mutations

Cancer occurs due to changes in DNA called mutations that affect the way your cells work and grow.4,5

Each person’s cancer is unique because DNA mutations between cancers differ in type and number.6,7

Even if you have the same type of cancer as someone else, your DNA mutations may differ, and you may need different treatment.6–8

To find out what mutations you may have in your DNA, your care team will take a biopsy to test your cancer.

If certain mutations are found in your cancer cells’ DNA, your doctor may be able to give you a more precise treatment based on this finding. There might be cases where no relevant mutations are found. This is also valuable information, supporting further treatment planning.6–11

Knowing the mutations in your cancer can help you and your doctor understand your treatment options, thereby personalising your treatment.6–11


What is comprehensive genomic profiling?

There are several different types of genomic testing, which include single biomarker testing, hotspot testing and comprehensive genomic profiling. They all test your cancer sample for DNA mutations but work in different ways.

Single biomarker testing and hotspot testing only look for predefined individual mutations within limited regions on your cancer cells’ DNA.12,13

Comprehensive genomic profiling provides a more complete picture of your cancer by searching for multiple mutations across a broad region of your cancer cells’ DNA. This increases your chances of finding important mutations right away and may also increase the chance of finding a more precise treatment for you.1–3


Foundation Medicine’s services use comprehensive genomic profiling



Our services

Foundation Medicine offers a high-quality portfolio of comprehensive genomic profiling services that may help you and your doctor better understand your treatment options.1,14–17

There are different tests available for patients with different types of cancer.

FoundationOne®CDx, FoundationOne®Liquid and FoundationOne®Heme search for multiple mutations in your cancer sample to increase your chances of finding a more precise treatment and help personalise your cancer treatment plan.6–11,14–24

Your care team will receive a comprehensive report including the details on your tumour profile as well as therapies and clinical trials for you to discuss together and help guide your treatment plan.6–11,25

The following materials provide further information about FoundationOne CDx, FoundationOne Liquid and FoundationOne Heme:


Please contact your local

Foundation Medicine team to find out more


  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. Dong L et al. Curr Genomics 2015; 16: 253–263.
  3. Sicklick JK et al. Nat Med 2019; 25: 744–750.
  4. American Cancer Society Glossary. Cancer. Available at: (Accessed August 2019).
  5. American Cancer Society Glossary. Mutations. Available at: (Accessed August 2019)
  6. Baumgart M et al. Am J Hematol Oncol 2015; 11: 10–13.
  7. Schwaederle M, Kurzrock R. Oncoscience 2015; 2: 779–780.
  8. Heim D et al. Int J Cancer 2014; 135: 2362–2369.
  9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. V.2.2019, 2018. Available at: (Accessed August 2019).
  10. Ohashi K et al. Clin Cancer Res 2013; 19: 2584–2591.Rozenblum AB et al. J Thorac Oncol 2017; 12: 258–268.
  11. Naidoo J, Drilon A. Am J Hematol Oncol 2014: 10: 4–11.
  12. Suh JH et al. Oncologist 2016; 21: 684–691.
  13. FoundationOne®CDx Technical Specifications, 2018. Available at: (Accessed August 2019).
  14. FoundationOne®Liquid Technical Specifications, 2018. Available at: (Accessed August 2019).
  15. Clark TA, et al. J Mol Diagn 2018; 20: 686–702.
  16. FoundationOne®Heme Technical Specifications, 2017. Available at: (Accessed August 2019).
  17. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Soft Tissue Sarcoma. V.2.2019, 2019. Available at: updated.aspx (Accessed August 2019).
  18. Groisberg R et al. Oncotarget 2017; 8: 39254–39267.
  19. Gounder M et al. Presented at ASCO Annual Meeting 2017, Chicago (Illinois), USA: Abstract 11001.
  20. He J et al. Blood 2016; 127: 3004–3014.
  21. Galanina N et al. Cancers (Basel) 2018; 11.pii: E11.
  22. Goodman AM et al. JCO Precis Oncol 2017. doi: 10.1200/PO.16.00004.
  23. Heuck C et al. Blood 2015; 126: 369.
  24. FoundationOne®CDx Sample report 2018. Available at: (Accessed August 2019).